A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE013 (USA) · Dr. Clarke
consented 2022-09-17
Adverse events
Grade 4 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-11-02 (study day 32); relationship: not assessed; serious criteria: life-threatening
Grade 1 Constipation — outcome: RECOVERED/RESOLVED; onset 2022-12-26 (study day 86); relationship: Y
Grade 3 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-01-12 (study day 103); relationship: N
Grade 3 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-01-25 (study day 116); relationship: not assessed; serious criteria: hospitalization
Grade 2 Decreased appetite — outcome: UNKNOWN; onset 2023-04-25 (study day 206); relationship: Y
Grade 3 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2023-09-14 (study day 348); relationship: not assessed
Data queries
No data queries.